CryoPort, Inc. CYRX Biologistics Solutions — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by CryoPort, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: CryoPort, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about CryoPort, Inc.'s biologistics solutions — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CryoPort, Inc.'s biologistics solutions — revenue?
- CryoPort, Inc. (CYRX) reported biologistics solutions — revenue of $21.67M in Q1 2026.
- How has CryoPort, Inc.'s biologistics solutions — revenue changed year-over-year?
- CryoPort, Inc.'s biologistics solutions — revenue increased by 16.9% year-over-year, from $18.53M to $21.67M.
- What is the long-term trend for CryoPort, Inc.'s biologistics solutions — revenue?
- Over 2 years (2022 to 2025), CryoPort, Inc.'s biologistics solutions — revenue has grown at a -20.9% compound annual growth rate (CAGR), from $124.8M to $78.14M.
- What does biologistics solutions — revenue mean?
- This metric represents the total revenue generated from the company's specialized temperature-controlled supply chain and logistics services tailored for the life sciences industry. It reflects the demand for critical cold-chain infrastructure, including storage, transport, and logistics management for biopharmaceutical and reproductive medicine products. Tracking this revenue stream provides insight into the company's market penetration and the adoption rate of its core logistics solutions within the global healthcare sector.